New Cell Therapies for Central Nervous System Diseases Using IPSC-Derived Products

Continue reading →

Stem Cell Therapy, iPSC, Neurons

  • Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
  • Representative: CEO Chikafumi Yokoyama
  • Inquiries: CFO Daisuke Usui (TEL.045-475-3887)

Today, REPROCELL Inc. (“REPROCELL”) has entered into a partnership with Steminent Biotherapeutics Inc. (“Steminent”) to develop and commercialize Steminent’s allogeneic stem cell therapy product, Stemchymal, in Japan. This announcement is in response to the acceptance of the agreement from the board committee on the event date.

Continue reading →

Stem Cell Therapy